「Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective」
Yugo Chisaki, Nobuhiko Nakamura, Takako Komuro, Hirokatsu Nyuji, Mai Harano,
Noriaki Kitada.
Clin Drug Investig. 2025 Jun;45(6):317-326. doi: 10.1007/s40261-025-01445-8.
Clin Drug Investig. 2025 Jun;45(6):317-326. doi: 10.1007/s40261-025-01445-8.